Highlights Newsletter 1
This newsletter presents you the following key sessions:
1. Video-interview with Professor Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School
of Medicine, Athens, Greece
2. Classic Hodgkin lymphoma (cHL) patients with high-risk features have greater benefit from brentuximab vedotin
+ AVD versus ABVD compared with the overall study population
3. Anti-tumor activity of compound CAR T cells targeting both CLL1 and CD33 in a variety of CLL1+ and CD33+
leukemia cells in vitro and in vivo
4. Better response rates and increased MRD negativity with KRd compared to KCd in newly diagnosed multiple
myeloma patients, including high-risk patients
5. The combination of ruxolitinib and azacitidine is well tolerated with good responses in patients with myelofibrosis